Analytical Data
-
Gene name
CD52
-
简介
CD52 Protein carries and orients carbohydrates, indicating involvement in molecular transport and arrangement. It also has a specific role that is not fully understood. CD52's versatility prompts further investigation into its mechanisms and contributions. Understanding its targeted role can reveal insights into its functions and broader implications. CD52 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived CD52 protein, expressed by HEK293 , with C-hFc labeled tag.
- Application
-
Alternative Names
CAMPATH-1; CD52 antigen; CDw52; Epididymal secretory protein E5; He5
-
Species
Cynomolgus
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 95% as determined by reducing SDS-PAGE.
-
Uniprot
F6QMS2
-
Expression Region
S25-S35
-
Protein Length
Partial
-
Molecular Weight
35-46 kDa.
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD52 is a glycoprotein expressed on the surface of certain immune cells, playing a crucial role in immune regulation. Research on CD52 has gained significant traction due to its implications in various diseases, particularly in hematological malignancies and autoimmune disorders. The protein is the target of the monoclonal antibody alemtuzumab, which has been utilized in the treatment of chronic lymphocytic leukemia (CLL) and multiple sclerosis (MS). By depleting CD52-expressing T and B lymphocytes, alemtuzumab effectively modulates the immune response, offering therapeutic benefits. However, the development of CD52-targeting therapies raises questions about potential side effects, such as increased susceptibility to infections and the risk of secondary malignancies. As a result, understanding the structure, function, and signaling pathways associated with CD52 is critical for optimizing existing treatments and developing new immunotherapeutic strategies. Recent advances in recombinant protein technology have enabled the production of CD52 fusion proteins, which can be used to investigate its biological functions and interactions. Additionally, these recombinant forms can serve as valuable tools for diagnostic and therapeutic applications, enhancing our capacity to manipulate the immune system. Through ongoing research, CD52 remains a promising candidate for novel treatment modalities aimed at improving patient outcomes in a range of immunological conditions.
